HPV-related cancers in people living with HIV — viral and immune factors tied to survival
Official title: Project 1: Exploring viral and immunological factors of HPV associated cancers in PLWH and its relation to survival
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11414774 · Data updated 2026-11-12
Researchers are looking at how HPV and immune system differences in people living with HIV affect outcomes from HPV-related cancers.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | August 3, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $89,319 |
| NIH project number | 3U54CA277834-03S1 |
| Project ID | NIH-11414774 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people living with HIV who have an HPV-related cancer (for example anal, cervical, vulvar, penile, or oropharyngeal cancer) and receive care at a participating site.
✕Less likely to help
People without HPV-related cancers or those not willing or able to provide tumor or blood samples are unlikely to benefit directly from participation.
What this research studies
You may be asked to provide tumor tissue, blood, and clinical information so researchers can compare the viral and immune features of HPV-related cancers in people with and without HIV. The team will analyze tumor viral content, immune cell types and signaling, and links between those features and how long patients survive after cancer. They plan to include patients from sites including sub-Saharan Africa as well as U.S. centers and use those data to see whether immune-based treatments might help people living with HIV. Findings will be used to design better screening, prevention, and treatment approaches for HPV-related cancers in this population.
Why it matters
Potential benefit: If successful, this work could lead to better ways to detect and treat HPV-related cancers in people living with HIV, including more targeted use of immunotherapy.
How similar studies have gone: Immune therapies have helped some patients with HPV-driven cancers, but studies specifically focused on people living with HIV are limited and the approach is relatively novel for this group.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Botha, Matthys Hendrik — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Botha, Matthys Hendrik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.